



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 011823-004920US  
PDL0049-20

Assistant Commissioner for Patents  
Washington, D.C. 20231

On October 16, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Paula Faulk Hurley

**RECEIVED**

OCT 24 2001

TECH CENTER 1600/2900

# 6/C  
KD  
11-301

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Tso et al.

Application No.: 09/618,380

Filed: July 18, 2000

For: **BISPECIFIC ANTIBODY  
EFFECTIVE TO TREAT B-CELL  
LYMPHOMA AND CELL LINE**

Examiner: Unassigned

Art Unit: 1642

**PRELIMINARY AMENDMENT**

**AND**

**COMMUNICATION UNDER 1.821-1.825**

BOX Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. § 1.821-1.825, mailed September 28, 2001, Applicants submit that the computer readable form in this application, 09/618,380, is identical with that filed in Application 08/397,411, filed March 1, 1995. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application.

It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included for incorporation into the Specification.